Rajan MB, Bhardwaj A, Singh S, et al. - Researchers conducted this double‐blind randomized control trial to compare hair regrowth and local side effects of various concentrations of intralesional triamcinolone acetonide (TA) in scalp alopecia areata (AA) utilizing clinical and dermoscopic parameters. Between March‐2018 and August‐2019, four treatment groups [10‐mg/ml, 5‐mg/ml, 2.5‐mg/ml TA and normal saline] were analyzed. Seventy-five patients (121‐patches) completed the study out of 105 patients (168‐AA patches). At the cost of increased adverse effects, 10‐mg/ml TA demonstrated a comparatively better response. It may be better to start with 2.5‐mg/ml intralesional TA in limited scalp AA patients based on the clinical benefit and adverse risk assessment from the study. Based on the serial clinical and dermoscopic response, it can be inferred that TA concentration can be increased as a step‐up regimen.